Rani Therapeutics Holdings, Inc. · NASDAQ:RANI
Raymond Debbane reported a 9.99% stake in Rani Therapeutics Holdings, Inc. (Schedule 13G)
Event Oct 16, 2025 · Filed Oct 23, 2025
Raymond Debbane reported a 9.99% stake in Rani Therapeutics Holdings, Inc., 9,825,911 shares, as a passive investor on Oct 16, 2025. Filed Oct 23, 2025 (Schedule 13G).
- Stake
- 9.99%
- Shares
- 9,825,911
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 8 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Invus Public Equities, L.P. | 8.80% | 8,617,378 |
| Invus Public Equities Advisors, LLC | 8.80% | 8,617,378 |
| Invus Global Management, LLC | 8.80% | 8,617,378 |
| Siren, L.L.C. | 8.80% | 8,617,378 |
| Avicenna Life Sci Master Fund LP | 1.30% | 1,208,533 |
| Avicenna Life Sci Master GP LLC | 1.30% | 1,208,533 |
| Ulys, L.L.C. | 1.30% | 1,208,533 |
| Raymond Debbane | 9.99% | 9,825,911 |
Source
Related
- Rani Therapeutics Holdings, Inc.
- Invus Public Equities, L.P.
- Rani Therapeutics Holdings, Inc. shareholders
- Form 4 · Imran Talat · Sep 29, 2026
- Form 4 · Javadi Alireza · Sep 29, 2026
- Schedule 13G/A · Ra Capital Management, L.P. · Aug 14, 2026
- Schedule 13G/A · Vanguard Capital Management LLC · Jul 31, 2026
- Form 4 · Imran Mir A · Jul 23, 2026